The mission of the Melanoma Research Alliance (MRA) is to end suffering and death due to melanoma by collaborating with all stakeholders to accelerate powerful research, advance cures for all patients, and prevent more melanomas.
The grant program from MRA supports pre-clinical, translational, and early clinical research aimed at making high-impact, near-term advancements in the prevention, detection, diagnosis, and treatment of melanoma. It seeks proposals that bridge the gap in translational science, turning scientific discoveries into clinical applications for high-risk individuals and patients with melanoma. Proposals could focus on prevention through understanding environmental, epidemiological, and biological factors leading to melanoma; development of innovative detection and diagnostic techniques; and new treatments that could include immunotherapy, targeting molecular mechanisms, the tumor microenvironment or microbiome, combination therapies, and the development of novel biomarkers. The grant program includes an Academic-Industry Partnership Award to boost translational research through collaboration between academia and industry, providing funding up to $300,000 per year for three years, with matching or exceeding contributions from an industry partner.